Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jay P,Reddy

第一单位： Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

作者： Jay P,Reddy ^[1] ; Mike,Hernandez ^[2] ; Jillian R,Gunther ^[1] ; Bouthaina S,Dabaja ^[1] ; Geoffrey V,Martin ^[1] ; Wen,Jiang ^[1] ; Mani,Akhtari ^[1] ; Pamela K,Allen ^[3] ; Bradley J,Atkinson ^[1] ; Grace L,Smith ^[4] ; Chelsea C,Pinnix ^[1] ; Sarah A,Milgrom ^[1] ; Zeinab,Abou Yehia ^[1] ; Eleanor M,Osborne ^[1] ; Yasuhiro,Oki ^[1] ; Hun,Lee ^[5] ; Fredrick,Hagemeister ^[5] ; Michelle A,Fanale ^[5]

作者单位： Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[1] Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[2] Department of Radiation Oncology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA. ^[3] Department of Clinical Pharmacy Services, University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[4] Department of Lymphoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[5]

关键词 Hodgkin lymphoma lymphocyte neutrophil platelet refractory relapse